Overview

Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis

Status:
Completed

Trial end date:
2004-10-20

Target enrollment:

Participant gender:

Summary

The primary objective of the study was to compare the percentage of subjects in remission after 8 weeks of treatment with SPD476, 2.4 g/day once daily vs placebo and SPD476 4.8 g/day once daily versus placebo

Phase:

Phase 3

Details

Lead Sponsor:

Shire

Treatments:

Mesalamine